RTP Mobile Logo
Cases from the Community: Clinical Investigators Provide Their Perspectives on Emerging Research and Actual Patients with Gastrointestinal Cancers — A Special Video Supplement
Released October 2017

A special supplement to a CME symposium held at the 2017 ASCO Annual Meeting featuring expert comments on the application of emerging research to patient care. Featuring perspectives from Dr Michael J Overman and Prof Eric Van Cutsem. (Video Program)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of colorectal, gastroesophageal, pancreatic and hepatocellular cancer.

    Given the prevalent nature of the disease, extensive resources are allocated to colorectal cancer (CRC) research and education. Interestingly, however, although individually less frequently encountered, the collection of other “non-CRC” gastrointestinal (GI) cancers accounts for more per annum cancer-related deaths than those attributed to tumors of the colon and rectum combined. Among this collection of distinct tumor types, a few areas in particular — namely gastric, pancreatic and hepatocellular cancer — have witnessed several recent advances that have altered or have the potential to drastically alter current treatment considerations and approaches.

    This program features discussions with 2 faculty after a CME symposium held during the 2017 ASCO Annual Meeting regarding cases submitted by practicing general oncologists and review of the published literature surrounding the clinical situations explored. By providing information on the latest research developments and their potential impact on routine practice, this activity is designed to assist medical oncologists, hematology-oncology fellows and other healthcare providers with the formulation of up-to-date clinical management strategies for both CRC and select non-CRC GI cancers.


    • Develop a long-term care plan for individuals diagnosed with metastatic CRC, considering factors such as biomarker profile, exposure to prior systemic therapy, symptomatology and performance status.
    • Evaluate recent data on therapeutic advances and changing practice standards in colorectal, gastric, pancreatic and hepatocellular cancer, and integrate this information, as appropriate, into current clinical care.
    • Communicate the benefits and risks of existing and emerging systemic interventions to patients with locally advanced or metastatic hepatocellular cancer.
    • Counsel patients regarding the management of side effects associated with commonly used systemic agents and regimens in the management of advanced colorectal, gastric, pancreatic and hepatocellular cancer.
    • Recall the rationale for and clinical data with anti-PD-1 and/or anti-PD-L1 antibodies for patients with GI cancers.
    • Describe the proposed mechanisms of action of and recall new data with investigational agents demonstrating promising activity in colorectal, gastric, pancreatic and hepatocellular cancer, and use this information to refer appropriate patients for participation in ongoing trials.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Michael J Overman, MD
    Associate Professor
    Department of Gastrointestinal (GI) Medical Oncology
    Division of Cancer Medicine
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: Bristol-Myers Squibb Company, MedImmune Inc, Roche Laboratories Inc, Sirtex Medical Ltd; Contracted Research: Amgen Inc, MedImmune Inc, Roche Laboratories Inc, Sirtex Medical Ltd; Other Remunerated Activities: Merck.

    Eric Van Cutsem, MD, PhD
    Professor of Medicine
    Digestive Oncology
    University Hospital Gasthuisberg/Leuven
    Leuven, Belgium

    Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Novartis, Roche Laboratories Inc, Sanofi Genzyme.

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Halozyme Inc, Ipsen Biopharmaceuticals Inc, Lilly and Taiho Oncology Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: October 2017
    Expiration date: October 2018

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Management of metastatic colorectal cancer (mCRC)

Important systemic treatment considerations for patients with pancreatic adenocarcinoma (PAD)

Current and future treatment of advanced gastric and gastroesophageal junction (GEJ) cancer

Recent advances in the management of hepatocellular carcinoma (HCC)

Select Publications